The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Yasmeen Rahimi - Piper Sandler & Co. - Analyst
: I'm very much looking forward to the data across both of the studies for this year. I guess, the first question is, you guys have shown in the earlier
stage really phenomenal dose responses in the EASI scores. So I would love to understand how you're thinking about dose response across the
three dose arms?
And then secondly, if you could just maybe remind us what is the criteria or responder analysis defined for patients to be eligible to go from the
induction phase to the maintenance phase? And I'll jump back in the queue.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 12, 2025 / 9:00PM, NKTR.OQ - Q4 2024 Nektar Therapeutics Earnings Call
Question: Julian Harrison - BTIG LLC - Analyst
: First, on the Phase IIb atopic dermatitis data expected next quarter. I'm wondering if you could talk about what kind of efficacy bar either on EASI
or IGA you think would be commercially viable and worthwhile to advance REZPEG into pivotal development?
Question: Julian Harrison - BTIG LLC - Analyst
: And then one more, if I may. I'm curious how you're thinking about your rights to dapirolizumab in light of the recent litifilimab royalty monetization?
Are there any differences compared to litifilimab that are worth noting?
Question: Jay Olson - Oppenheimer & Co. Inc - Analyst
: Congrats on all the progress and thank you for providing this update. Maybe another question on the top line Phase II atopic dermatitis results in
the second quarter. Can you just talk about the scope of data that you're planning to share in that top line release and maybe some of the secondary
endpoints we should be looking for? And then also, what do you think the profile would be that would help you capture meaningful market share
in the first-line setting?
Question: Jay Olson - Oppenheimer & Co. Inc - Analyst
: And if I could sneak in a question on 255. Can you just talk about any updates on timing or expectations for the interim PFS results from the JAVELIN
Bladder Medley study and what we should be looking for there?
Question: Roger Song - Jefferies LLC - Analyst
: I have a quick one related to the Phase II atopic dermatitis. Given the enrolment you have completed compared to the recent atopic dermatitis
trial, what's your expectation in terms of the patient baseline? And then how will that impact the -- particularly on the placebo arm, what's your
expectation there?
Question: Mayank Mamtani - B. Riley Securities, Inc. - Analyst
: Could you touch on -- just a related question to the last comment, JZ. Anything you can touch on the screen failure rate you've seen on this extra
stringent criteria you're using and how that may compare to some other studies that have been done around screening and then randomization?
And then I have a quick follow-up.
Question: Mayank Mamtani - B. Riley Securities, Inc. - Analyst
: And then the escape piece in the protocol, how patients go on the escape arm? Could you just remind me how that's kind of structured for induction
and maintenance?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 12, 2025 / 9:00PM, NKTR.OQ - Q4 2024 Nektar Therapeutics Earnings Call
And then lastly, just high level, the read-through from AD data set to the REZOLVE-AA study, any translational markers you're looking at would be
helpful to know?
Question: Arthur He - H.C. Wainwright & Co., LLC - Analyst
: So JZ, thanks for the additional color on the dose regimen for the AD study. I just want to follow up a little bit on the rationale to pick those three
regimen arms. So why not go for a higher dosing regimen than the 24 microgram per kilo Q2W? Yes. And then I had a follow-up on the trial as well.
Question: Arthur He - H.C. Wainwright & Co., LLC - Analyst
: So -- and the second question is also regarding probably both AD and the AA study. Could you remind us how is the stratification in both study
based in terms of the disease severity wise, how that could be decided for the stratification?
Question: Arthur He - H.C. Wainwright & Co., LLC - Analyst
: So how about AD study?
| 
